Diflunisal Targeted Delivery Systems: A Review

Diflunisal is a well-known drug for the treatment of rheumatoid arthritis, osteoarthritis, primary dysmenorrhea, and colon cancer. This molecule belongs to the group of nonsteroidal anti-inflammatory drugs (NSAID) and thus possesses serious side effects such as cardiovascular diseases risk developme...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Petr Snetkov, Svetlana Morozkina, Roman Olekhnovich, Mayya Uspenskaya
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	diflunisal drug delivery systems amyloidosis release profile Technology T Electrical engineering. Electronics. Nuclear engineering TK1-9971 Engineering (General). Civil engineering (General) TA1-2040 Microscopy QH201-278.5 Descriptive and experimental mechanics QC120-168.85
Acceso en línea:	https://doaj.org/article/e6524fa81cd04d16aa9dc6fe120d628e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e6524fa81cd04d16aa9dc6fe120d628e
record_format	dspace
spelling	oai:doaj.org-article:e6524fa81cd04d16aa9dc6fe120d628e2021-11-11T18:11:37ZDiflunisal Targeted Delivery Systems: A Review10.3390/ma142166871996-1944https://doaj.org/article/e6524fa81cd04d16aa9dc6fe120d628e2021-11-01T00:00:00Zhttps://www.mdpi.com/1996-1944/14/21/6687https://doaj.org/toc/1996-1944Diflunisal is a well-known drug for the treatment of rheumatoid arthritis, osteoarthritis, primary dysmenorrhea, and colon cancer. This molecule belongs to the group of nonsteroidal anti-inflammatory drugs (NSAID) and thus possesses serious side effects such as cardiovascular diseases risk development, renal injury, and hepatic reactions. The last clinical data demonstrated that diflunisal is one of the recognized drugs for the treatment of cardiac amyloidosis and possesses a survival benefit similar to that of clinically approved tafamidis. Diflunisal stabilizes the transthyretin (TTR) tetramer and prevents the misfolding of monomers and dimers from forming amyloid deposits in the heart. To avoid serious side effects of diflunisal, the various delivery systems have been developed. In the present review, attention is given to the recent development of diflunisal-loaded delivery systems, its technology, release profiles, and effectiveness.Petr SnetkovSvetlana MorozkinaRoman OlekhnovichMayya UspenskayaMDPI AGarticlediflunisaldrug delivery systemsamyloidosisrelease profileTechnologyTElectrical engineering. Electronics. Nuclear engineeringTK1-9971Engineering (General). Civil engineering (General)TA1-2040MicroscopyQH201-278.5Descriptive and experimental mechanicsQC120-168.85ENMaterials, Vol 14, Iss 6687, p 6687 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diflunisal drug delivery systems amyloidosis release profile Technology T Electrical engineering. Electronics. Nuclear engineering TK1-9971 Engineering (General). Civil engineering (General) TA1-2040 Microscopy QH201-278.5 Descriptive and experimental mechanics QC120-168.85
spellingShingle	diflunisal drug delivery systems amyloidosis release profile Technology T Electrical engineering. Electronics. Nuclear engineering TK1-9971 Engineering (General). Civil engineering (General) TA1-2040 Microscopy QH201-278.5 Descriptive and experimental mechanics QC120-168.85 Petr Snetkov Svetlana Morozkina Roman Olekhnovich Mayya Uspenskaya Diflunisal Targeted Delivery Systems: A Review
description	Diflunisal is a well-known drug for the treatment of rheumatoid arthritis, osteoarthritis, primary dysmenorrhea, and colon cancer. This molecule belongs to the group of nonsteroidal anti-inflammatory drugs (NSAID) and thus possesses serious side effects such as cardiovascular diseases risk development, renal injury, and hepatic reactions. The last clinical data demonstrated that diflunisal is one of the recognized drugs for the treatment of cardiac amyloidosis and possesses a survival benefit similar to that of clinically approved tafamidis. Diflunisal stabilizes the transthyretin (TTR) tetramer and prevents the misfolding of monomers and dimers from forming amyloid deposits in the heart. To avoid serious side effects of diflunisal, the various delivery systems have been developed. In the present review, attention is given to the recent development of diflunisal-loaded delivery systems, its technology, release profiles, and effectiveness.
format	article
author	Petr Snetkov Svetlana Morozkina Roman Olekhnovich Mayya Uspenskaya
author_facet	Petr Snetkov Svetlana Morozkina Roman Olekhnovich Mayya Uspenskaya
author_sort	Petr Snetkov
title	Diflunisal Targeted Delivery Systems: A Review
title_short	Diflunisal Targeted Delivery Systems: A Review
title_full	Diflunisal Targeted Delivery Systems: A Review
title_fullStr	Diflunisal Targeted Delivery Systems: A Review
title_full_unstemmed	Diflunisal Targeted Delivery Systems: A Review
title_sort	diflunisal targeted delivery systems: a review
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/e6524fa81cd04d16aa9dc6fe120d628e
work_keys_str_mv	AT petrsnetkov diflunisaltargeteddeliverysystemsareview AT svetlanamorozkina diflunisaltargeteddeliverysystemsareview AT romanolekhnovich diflunisaltargeteddeliverysystemsareview AT mayyauspenskaya diflunisaltargeteddeliverysystemsareview
_version_	1718431916394283008

Diflunisal Targeted Delivery Systems: A Review

Ejemplares similares